Last reviewed · How we verify
IV Loop Diuretics
IV loop diuretics inhibit the sodium-potassium-chloride co-transporter in the thick ascending limb of the loop of Henle, increasing urinary sodium and water excretion.
IV loop diuretics inhibit the sodium-potassium-chloride co-transporter in the thick ascending limb of the loop of Henle, increasing urinary sodium and water excretion. Used for Acute decompensated heart failure with fluid overload, Edema associated with congestive heart failure, renal disease, or hepatic cirrhosis, Hypertension.
At a glance
| Generic name | IV Loop Diuretics |
|---|---|
| Sponsor | Nuwellis, Inc. |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Loop diuretics block the Na-K-2Cl cotransporter on the apical membrane of thick ascending limb cells, preventing reabsorption of these electrolytes and creating an osmotic gradient that reduces water reabsorption throughout the nephron. This results in potent diuresis and is particularly effective in patients with reduced glomerular filtration rate or acute decompensated heart failure. IV formulation allows rapid onset of action in acute clinical settings.
Approved indications
- Acute decompensated heart failure with fluid overload
- Edema associated with congestive heart failure, renal disease, or hepatic cirrhosis
- Hypertension
- Pulmonary edema
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (with high doses)
- Hyperglycemia
- Hypotension
- Dehydration
- Electrolyte imbalances
Key clinical trials
- Natriuresis-guided Depletion After Cardiac Surgery (NA)
- Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure (PHASE1)
- Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients (NA)
- Ultrafiltration Versus IV Diuretics in Worsening Heart Failure (NA)
- EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) (NA)
- Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload (PHASE4)
- Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure (PHASE2, PHASE3)
- Optimized Treatment of Pulmonary Edema or Congestion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Loop Diuretics CI brief — competitive landscape report
- IV Loop Diuretics updates RSS · CI watch RSS
- Nuwellis, Inc. portfolio CI